Authors,Title,Year,Source title,Volume,Issue,Art. No.,Page start,Page end,Page count,Cited by,DOI,Link,Affiliations,Authors with affiliations,Abstract,Author Keywords,Index Keywords,Molecular Sequence Numbers,Chemicals/CAS,Tradenames,Manufacturers,Funding Details,References,Correspondence Address,Editors,Sponsors,Publisher,Conference name,Conference date,Conference location,Conference code,ISSN,ISBN,CODEN,PubMed ID,Language of Original Document,Abbreviated Source Title,Document Type,Source,EID
"McDonald K.J., Martin G.P.","Transition to CFC-free metered dose inhalers - Into the new millennium",2000,"International Journal of Pharmaceutics","201","1",,"89","107",,,10.1016/S0378-5173(00)00401-4,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0034658554&partnerID=40&md5=cd2f6331d2eebe33a4364b6de8070d2b","Medicines Control Agency, Mkt. Towers, 1 Nine Elms Ln., S., London, United Kingdom; Department of Pharmacy, King's Coll. London, Franklin-W., London, United Kingdom","McDonald, K.J., Medicines Control Agency, Mkt. Towers, 1 Nine Elms Ln., S., London, United Kingdom; Martin, G.P., Department of Pharmacy, King's Coll. London, Franklin-W., London, United Kingdom","Metered dose inhalers (MDIs) are the most popular vehicle for drug delivery into the lungs and some 500 million are manufactured each year. All MDIs marketed prior to 1995 contained chlorofluorocarbons (CFC) as a propellant. These are implicated in the depletion of stratospheric ozone and, except for specific exemptions, their production has been banned since 1996 under the terms of the Montreal Protocol. Hydrofluoroalkanes have been identified as suitable alternatives for MDI propellants but their physico-chemical properties differ significantly from CFCs and an extensive redevelopment and testing programme has been required to demonstrate the safety, quality and efficacy of HFA containing MDIs. Hydrofluoroalkanes contribute to global warming but the benefit to human health through continued MDI availability currently outweighs the environmental concern. Several HFA-MDIs have reached the market and the transition to replace existing CFC-MDIs is now underway. Copyright (C) 2000 Elsevier Science B.V.","Chlorofluorocarbons; Hydrofluoroalkanes; Metered dose inhalers","antiasthmatic agent; apaflurane; beclometasone; bitolterol; budesonide; carbuterol; chlorofluorocarbon; clenbuterol; cromoglycate disodium; dexamethasone; fenoterol; flunisolide; fluorinated hydrocarbon; fluticasone; formoterol; hexoprenaline; ipratropium bromide; nedocromil; norflurane; orciprenaline; oxitropium bromide; pirbuterol; procaterol; propellant; reproterol; salbutamol; salmeterol; terbutaline; triamcinolone; aerosol; article; asthma; chronic obstructive lung disease; drug delivery system; human; law; lung; market; metered dose inhaler; ozone layer; particle size; physical chemistry; pollution; priority journal; respiratory tract disease; Aerosol Propellants; Chlorofluorocarbons, Methane; Humans; Nebulizers and Vaporizers",,"Aerosol Propellants; Chlorofluorocarbons, Methane","hfa 134a; hfa 227",,,"Aiache, J.M., Bull, H., Ganderton, D., Haywood, P., Olsson, B., Wright, P., Inhalations: Collaborative study on the measurement of the fine particle dose using inertial impactors (1993) Pharmeuropa, 5 (4), pp. 386-389; Atkins, P.J., Barker, N.P., Mathisen, D., The design and development of inhalation drug delivery systems (1992) Pharmaceutical Inhalation Aerosol Technology, pp. 155-185. , A.J. Hickey. NY: Marcel Dekker; Blondino, F.E., (1995) Novel Solution Aerosols for Inhalation, , Virginia Commonwealth University, USA. Ph.D. Thesis; Blondino, F.E., Byron, P.R., Drug stability in non-aqueous solutions-influence of surfactant concentration (1996) Respiratory Drug Delivery V, pp. 125-131. , R.N. Dalby, P.R. Byron, & S.J. Farr. Buffalo Grove: Interpharm Press; Guidelines on the management of asthma (1993) Thorax, 48, pp. S1-S24. , Statement by the British Thoracic Society, the British Paediatric Association, the Research Unit of the Royal College of Physicians of London, the King's Fund Centre, the National Asthma Campaign, the Royal College of General Practitioners, the General Practitioners in Asthma Group, the British Association of Accident and Emergency Medicine, and the British Paediatric Respiratory Group; Byron, P.R., Towards the rational formulation of metered dose inhalers (1992) J. Biopharm. Sci., 33, pp. 001-009; Byron, P.R., Miller, N.C., Blondino, F.E., Visich, J.E., Ward, G.H., Some aspects of alternative propellant solvency (1994) Respiratory Drug Delivery IV, pp. 231-242. , R.N. Dalby, P.R. Byron, & S.J. Farr. Buffalo Grove: Interpharm Press; Chan, H.K., Gonda, I., Development of a systematic theory of suspension inhalation aerosols II: Aggregates of monodisperse particles nebulized in polydisperse droplets (1988) Int. J. Pharm., 41, pp. 147-157; Chua, H.L., Collins, G.G., Newbury, A.M., The influence of age on aerosol deposition in children with cystic fibrosis (1994) Eur. Resp. J., 7, pp. 2185-2191; Clark, A.R., Gonda, I., Newhouse, M.T., Towards meaningful laboratory tests for evaluation of pharmaceutical aerosols (1998) J. Aerosol Med., 11 (SUPPL.1), pp. 1-S7; (1994) Results of the Co-ordinated Review of 1,1,1,2-tetrafluoroethane HFC-134a, , Committee for Proprietary Medicinal Products European Commission, Directorate General III, Industry, Brussels. 13 July; (1995) Results of the Co-ordinated Review of 1,1,1,2,3,3,3-heptafluoropropane (HFC-227), , Committee for Proprietary Medicinal Products CPMP/503/95 The European Agency for the Evaluation of Medicinal Products, London. 13 September; Communication from the Commission to the Council and the European Parliament: Strategy for the phaseout of CFCs in metered dose inhalers (1998) Official Journal of the European Communities, p. 603. , COM; Cooper, D.W., Methods of size distribution data analysis and presentation (1993) Aerosol Measurement, pp. 206-232. , K. Willeke, & P. Baron. NY: Van Nostrand Reinhol; (1999) Current Problems in Pharmacovigilance, 25, pp. 5-6. , Committee on Safety of Medicines and the Medicines Control Agency, London; Cyr, T.D., Graham, S.J., Li, Y.R., Lovering, E.G., Low first spray drug content in albuterol metered dose inhalers (1991) Pharm. Res., 8 (5), pp. 658-660; Dalby, R.N., Tiano, S.L., Hickey, A.J., Medical devices for the delivery of therapeutic aerosols to the lungs (1996) Inhalation Aerosols: Physical and Biological Basis for Therapy, pp. 441-473. , A.J. Hickey. NY: Marcel Dekker; Davies, R.J., Stampone, P., O'Connor, B.J., Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose (1998) Resp. Med., 92 (SUPPL. A), pp. 23-31; Davies, R., Improvements in delivery with an extra fine beclomethasone aerosol (1998) Int. J. Clin. Pract., 96, pp. 28-32; Ensuring patient care. The role of the HFC MDI (1997) International Pharmaceutical Aerosol Consortium, , c/o Gardner, Carton & Douglas, 1301 K St., NW, Suite 900 East Tower, Washington, DC; Evans, R.M., Farr, S.J., Armstrong, N.A., Chatham, S.M., Formulation and in vitro evaluation of pressurised inhalation aerosols containing isotropic systems of lecithin and water (1991) Pharm.Res., 8, pp. 629-631; Evans, R.M., Farr, S.J., The development of novel, pressurized aerosols formulated as solutions (1992) J. Biopharm. Sci., 3 (1-2), pp. 33-40; European Pharmacopoeia, third edition (1997) Microbial Quality of Pharmaceutical Preparations, pp. 287-288. , Council of Europe, Strasbourg; Farman, J.C., Gardiner, B.G., Shanklin, J.D., Large losses of total ozone over Antarctica reveal serious ClOx/NOx interaction (1985) Nature, 325, pp. 207-210; Gonda, I., Development of a systematic theory of suspension inhalation aerosols I: A framework to study the effects of aggregation on the aerodynamic behaviour of drug particles (1985) Int. J. Pharm., 27, pp. 99-116; Gonda, I., Targetting by deposition (1992) Pharmaceutical Inhalation Aerosol Technology, pp. 155-185. , A.J. Hickey. NY: Marcel Dekker; Gorman, W.G., Carroll, F.A., Aerosol particle-size determination using laser holography (1993) Pharm. Technol., 34-37; Graham, S.J., Lawrence, R.C., Ormsby, E.D., Pike, R.K., Particle size distribution of single and multiple sprays of salbutamol metered dose inhalers (1995) Pharm. Res., 12 (9), pp. 1380-1384; Hallworth, G.W., The formulation and evaluation of pressurised metered-dose inhalers (1987) Drug Delivery to the Respiratory Tract, pp. 87-118. , D. Ganderton, & T. Jones. Chichester: Ellis Horwood; Harnor, K.J., Perkins, A.C., Wastie, M., Effect of vapour pressure on the deposition pattern from solution phase metered dose inhalers (1993) Int J. Pharm., 95, pp. 111-116; Harrison, L.I., Dahl, D.R., Cline, A., Pharmacokinetics and dose proportionality of beclomethasone from three strengths of CFC-free beclomethasone dipropionate metered dose inhaler (1997) Biopharm. Drug Disp., 18 (7), pp. 635-643; Health Service Circular 1998/180 (1998) Phase out of CFC Containing Metered Dose Inhalers for the Treatment of Asthma and COPD, , NHS Executive, Department of Health, PO Box 410, Wetherby, UK. 23 October; Hickey, A.J., Summary of common approaches to pharmaceutical aerosol administration (1992) Pharmaceutical Inhalation Aerosol Technology, pp. 255-288. , A.J. Hickey. NY: Marcel Dekker Inc; Hickey, A.J., Dunbar, C.A., A new millennium for inhaler technology (1997) Pharm. Technol., pp. 116-125; Howard, P.H., Hanchett, A., Chlorofluorocarbon sources of environmental contamination (1975) Science, 189, pp. 217-218; Howlett, D.J., Colwell, J., Improvements in extractables from pMDI elastomer systems (1997) In: Drug Delivery to the Lungs, 8, pp. 36-38. , The Aerosol Society, Bristol; Jager, P.D., De Stefano, G.A., McNamara, D.P., Particle-size measurement using right angle light scattering (1993) Pharm. Technol., 17 (4), pp. 102-103; June, J.S., Schultz, R.B., Miller, N.C., A conceptual model for development of pressurised metered dose hydrofluoroalkane based inhalation aerosols (1994) Pharm. Technol., 18 (10), pp. 40-52; June, D.S., Ross, D., Improvements in dosing characteristics achieved with a new HFA salbutamol metered dose inhaler (1995) Eur. Resp. J., 8, p. 1235; Leach, C.L., Improved delivery of inhaled steroids to the large and small airways (1998) Resp. Med., 92 (SUPPL. A), pp. 3-8; Leach, C.L., Davidson, P.J., Boudreau, R.J., Improved airway targetting with CFC-free HFA-beclomethasone dipropionate metered-dose inhaler compared with CFC-beclomethasone (1998) Eur. Resp. J., 12, pp. 1346-1353; Lebelle, M.J., Pike, R.K., Graham, S.J., Ormsby, E.D., Bogard, H.A., Metered dose inhalers I: Drug content and particle size distribution of beclomethasone dipropionate (1996) J. Pharm. Biomed. Anal., 14, pp. 793-800; Lebelle, M.J., Graham, S.J., Ormsby, E.D., Duhaine, R.M., Lawrence, R.C., Pike, R.K., Metered-dose inhalers II: Particle size measurement variation (1997) Int. J. Pharm., 151, pp. 209-221; Li Wan Po, A., Practice checklist-CFC-free inhalers (1999) Pharm. J., 262, p. 249; Marple, V.A., Olson, B.A., Miller, N.C., The role of inertial particle collectors in evaluating pharmaceutical aerosols (1998) J. Aerosol Med., 11 (SUPPL. 1), pp. 139-S153; Martonen, T.B., Katz, I., Deposition patterns of polydisperse aerosols within human lungs (1993) J. Aerosol Med., 6, pp. 251-274; McFadden E.R., Jr., Improper patient techniques with metered dose inhalers: Clinical consequences and solutions to misuse (1995) J. Allergy Clin. Immunol., 96, pp. 278-283; Meakin, B.J., Stroud, N., An evaluation of some metered dose aerosols using a twin impinger sampling device (1983) J. Pharm. Pharmacol. Suppl., 35, pp. 7P; Meier, M., Xaver Fischer, F., Keller, M., Halfmann, H.-J., Influence of alternative propellants on microbial viability in comparison to chlorofluorocarbons (1996) Drugs Made in Germany, 39 (1), pp. 14-22; Milanowski, J., Qualtrough, J., Perrin, V.L., Inhaled beclomethasone with non-CFC propellant is equivalent to BDP-CFC for the treatment of asthma (1999) Resp. Med., 93, pp. 245-251; Milosovich, S.M., Particle size determination via cascade impaction (1992) Pharm. Technol., 16 (9), pp. 82-86; Molina, M.J., Rowland, F.S., Stratospheric sink for chlorofluoromethane: Chlorine atom catalysed destruction of ozone (1974) Nature, 274, pp. 810-812; (1987) Montreal Protocol on Substances That Deplete the Ozone Layer, 26, p. 1541. , 1LM; Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention (1995) NHBLI/WHO Workshop Report, , National Heart, Lung, and Blood Institute, National Institutes of Health, NIH publication number 95-3659; January 1995; Newhouse, M.T., The current laboratory determination of 'respirable mass' is not clinically relevant (1998) J. Aerosol Med., 11 (SUPPL.1), pp. 122-S132; Newman, S.P., Moren, F., Pavia, D., Corrado, O., Clarke, S.W., The effects of changes in metered volume and propellant vapour pressure on the deposition of pressurized inhalation aerosols (1982) Int. J. Pharm., 11, pp. 337-344; Niven, R.W., Aerodynamic particle size testing using a time of flight aerosol beam spectrometer (1993) Pharm. Technol., 17 (1), pp. 72-78; Noakes, T.J., CFC's their replacement and the ozone layer (1995) J. Aerosol Med., 8 (SUPPL. 1), pp. 3-S7; Padfield, J.M., Winterborn, I.K., Pover, G.M., Tattersfield, A., Correlation between inertial impaction performance and clinical performance of a bronchodilator aerosol (1983) J. Pharm. Pharmacol. Suppl., 35, pp. 10P; Padfield, J.M., Principles of drug administration to the respiratory tract (1987) Drug Delivery to the Respiratory Tract, pp. 75-86. , D. Ganderton, & T. Jones. Chichester: Ellis Horwood Ltd; Paskiet, D.M., Strategies for determining extractables from rubber packaging materials in drug products (1997) P.D.A. J. Pharm. Sci. Tech., 51 (6), pp. 248-251; Polli, G.P., Grim, W.M., Bacher, F.A., Yunker, M.H., Influence of formulation on aerosol particle size (1969) J. Pharm. Sci., 58, pp. 484-486; Prime, D., Atkins, P.J., Slater, A., Sumby, B., Review of dry powder inhalers (1997) Adv. Drug Deliv. Rev., 26, pp. 51-58; Purewal, T.S., Alternative propellants for metered dose inhalers (1998) Aero. Spray Rep., 37 (1112), pp. 20-25; Ranucci, J.A., Cooper, D., Sethachutkul, K., Effect of actuator design on metered-dose inhaler plume-particle size (1992) Pharm. Technol., 16 (3), pp. 84-92; Ranucci, J., Dynamic plume-particle size analysis using laser diffraction (1992) Pharm. Technol., 16 (10), pp. 108-114; Ranucci, J.A., Chen, F.C., Phase doppler anenometry: A technique for determining aerosol plume particle size and velocity (1993) Pharm. Technol., 17 (6), pp. 62-73; Rogers, D., Ganderton, D., Determining equivalence of inhaled medicines (1995) Resp. Med., 89, pp. 253-261; Sanders, P., Washington, N., Frier, M., Wilson, C.G., Feely, L.C., Washington, C., The deposition of solution-based and suspension-based aerosols from metered dose inhalers in healthy subjects and asthmatic patients (1997) STP Pharm. Sci., 7 (4), pp. 300-306; Shaw, R.J., Inhaled corticosteroids for adult asthma: Impact of formulation and delivery device on relative pharmacokinetics, efficacy and safety (1999) Resp. Med., 93, pp. 149-160; Smith, I.J., The challenge of reformulation (1995) J. Aerosol Med., 8 (1), pp. 19-S27; Smith, S.J., Bernstein, J.A., Therapeutic use of lung aerosols (1996) Inhalation Aerosols: Physical and Biological Basis for Therapy, pp. 233-272. , A.J. Hickey. NY: Marcel Dekker; Snell, N.J., The need for new propellants in MDI: Problems and solutions (1995) J. Pharm. Med., 5, pp. 153-160; Soine, W.H., Blondino, F.E., Byron, P.R., Chemical stability in pressurized inhalers formulated as solutions (1992) J. Biopharm. Sci., 3 (1-2), pp. 41-47; Steckel, H., Muller, B.W., Metered dose inhaler formulations with beclomethasone-17,21-dipropionate using ozone friendly propellant R 134a (1998) Euro. J. Pharm. Biopharm., 46, pp. 77-83; Stein, S.W., Olson, B.A., Variability in size distribution measurements obtained using multiple Andersen Mark II cascade impactors (1997) Pharm. Res., 14 (12), pp. 1718-1725; Tansey, I., Technological development of Airomir (salbutamol sulphate in CFC-free system) MDI (1995) Br. J. Clin. Pract. Suppl., 79, pp. 13-15; Tansey, I.P., Changing to CFC free inhalers: The technical and clinical challenges (1997) Pharm. J., 259, pp. 896-898; Tansey, I., The technical transition to CFC free inhalers (1997) Br. J. Clin. Pract. Suppl., 89, pp. 22-27; (1996) The Potential Effects of Ozone Depletion in the United Kingdom, , The Stationery Office ISBN 0-11-753313; Timsina, M.P., Martin, G.P., Marriott, C., Ganderton, D., Yianneskis, M., Drug delivery to the respiratory tract using dry powder inhalers (1994) Int. J. Pharm., 101, pp. 1-13; Tiwari, D., Goldman, D., Malick, W.A., Madan, P.L., Formulation and evaluation of albuterol metered dose inhalers containing tetrafluoroethane (P134a), a non-CFC propellant (1998) Pharm. Dev. Technol., 3 (2), pp. 163-174; Tiwari, D., Goldman, D., Dixit, S., Malick, W.A., Madan, P.L., Compatibility evaluation of metered dose inhalers with tetrafluoroethane (P134a), a non-CFC propellant (1998) Drug Dev. Ind. Pharm., 24 (4), pp. 345-352; Tzou, T.-Z., Pachuta, R.R., Coy, R.B., Schultz, R.K., Drug from selection in albuterol containing metered dose inhaler formulations and its impact on chemical and physical stability (1997) J. Pharm. Sci., 86 (12), pp. 1352-1357; (1999) UK Transition Strategy for CFC-based MDIs, , Department of the Environment, Transport and the Regions, Eland House, Bressenden Place, London. September; Vervaet, C., Byron, P.R., Drug-surfactant-propellant interactions in HFA-formulations (1999) Int. J. Pharm., 186, pp. 13-30; Ward, G.H., Schultz, R.K., Process induced crystallinity changes in albuterol sulphate and its effect on powder physical stability (1995) Pharm. Res., 12, pp. 773-779; Williams, G., Current trends in metered-dose valve technology (1995) Pharm. Market. Internat., pp. 173-174; Williams, G., Tcherevatchenkoff, A. Moisture transport into CFC-free metered dose inhalers (1997) In: Drug Delivery to the Lungs, 8, pp. 91-94. , The Aerosol Society, Bristol; Williams R.O. III, Liu, J., Koleng, J.J., Influence of metering chamber volume and water level on the emitted dose of a suspension based pMDI containing propellant 134a (1997) Pharm. Res., 14 (4), pp. 438-443; Williams R.O. III, Liu, J., Influence of formulation additives on the vapor pressure of hydrofluoroalkane propellants (1998) Int. J. Pharm., 166, pp. 99-103; Williams R.O. III, Repka, M., Liu, J., Influence of propellant composition on drug delivery from a pressurised metered-dose inhaler (1998) Drug Dev. Ind. Pharm., 24 (8), pp. 763-770","McDonald, K.J.; Medicines Control Agency, Market Towers, 1 Nine Elms Lane, London SW8 5NQ, United Kingdom",,,,,,,,03785173,,IJPHD,10867268,"English","Int. J. Pharm.",Article,Scopus,2-s2.0-0034658554
